Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
Public ClinicalTrials.gov record NCT01857206. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Observer Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Chicken Eggs (Fluvirin®), in Healthy Children and Adolescents 4 to 17 Years of Age.
Study identification
- NCT ID
- NCT01857206
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Vaccines
- Industry
- Enrollment
- 2,055 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 4 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2013
- Primary completion
- May 31, 2014
- Completion
- May 31, 2014
- Last update posted
- Dec 4, 2014
2013 – 2014
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 320, Novartis Investigational Site | Mobile | Alabama | 36608 | — |
| 312, Novartis Investigational Site | Ponte Vedra | Florida | 32081 | — |
| 313, Novartis Investigational Site | Augusta | Kansas | 67010 | — |
| 305, Novartis Investigational Site | Newton | Kansas | 67114 | — |
| 302, Novartis Investigational Site | Wichita | Kansas | 67205 | — |
| 301, Novartis Investigational Site | Wichita | Kansas | 67207 | — |
| 311, Novartis Investigational Site | Fremont | Nebraska | 68025 | — |
| 308, Novartis Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| 317, Novartis Investigational Site | Cleveland | Ohio | 44121 | — |
| 309, Novartis Investigational Site | Tulsa | Oklahoma | 74127 | — |
| 314, Novartis Investigational Site | Warwick | Rhode Island | 02886 | — |
| 319, Novartis Investigational Site | Mt. Pleasant | South Carolina | 29464 | — |
| 310, Novartis Investigational Site | Bristol | Tennessee | 37620 | — |
| 318, Novartis Investigational Site | Nashville | Tennessee | 37203 | — |
| 304, Novartis Investigational Site | Salt Lake City | Utah | 84109 | — |
| 306, Novartis Investigational Site | Salt Lake City | Utah | 84121 | — |
| 315, Novartis Investigational Site | Salt Lake City | Utah | 84124 | — |
| 303, Novartis Investigational Site | South Jordan | Utah | 84095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01857206, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 4, 2014 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01857206 live on ClinicalTrials.gov.